Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data [0.03%]
基于整合肿瘤基因表达和临床数据的机器学习预测转移性尿路上皮癌患者阿特朱单抗疗效
Chayanit Piyawajanusorn,Ghita Ghislat,Pedro J Ballester
Chayanit Piyawajanusorn
Atezolizumab is a treatment for metastatic urothelial carcinoma (mUC), yet only 23% of mUC patients benefit from it. Worse yet, accurately predicting such responders remains challenging, despite existing biomarkers. Here we employed eight m...
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study [0.03%]
Erdafitinib与化疗在抗程序性死亡-配体1治疗后进展的FGF受体改变的晚期或转移性尿路上皮癌中的比较：THOR三期研究中亚洲亚群的探索性分析
Nobuaki Matsubara,Yohann Loriot,Earle F Burgess et al.
Nobuaki Matsubara et al.
Introduction: The randomized phase 3 THOR study showed significantly longer survival with erdafitinib (pan-fibroblast growth factor receptor [FGFR] inhibitor) over chemotherapy in adults with FGFR-altered locally advanced...
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma [0.03%]
德鲁替康治疗恩沃卢单抗耐药转移性尿路上皮癌患者的临床疗效分析
M Sternschuss,N Toumbacaris,J P Das et al.
M Sternschuss et al.
Background: Sacituzumab govitecan (SG) is an antibody-drug conjugate associated with clinically meaningful responses as advanced-line treatment of metastatic urothelial carcinoma (mUC). Practically, SG has been most commo...
Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study) [0.03%]
一线系统性治疗在肾功能不全的局部晚期或转移性尿路上皮癌患者中的实际疗效：YUSHIMA研究结果分析
Tomoki Kimura,Motohiro Fujiwara,Yuya Maezawa et al.
Tomoki Kimura et al.
Objectives: To investigate the impact of renal impairment (RI) on the efficacy of first-line chemotherapy in patients with locally advanced or metastatic upper tract urothelial carcinoma (la/mUTUC). ...
Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial [0.03%]
恩fortumab vedotin联合派姆单抗治疗初治局部晚期或转移性尿路上皮癌：EV-302/KEYNOTE-A39三期临床试验的中位随访2.5年的结果
T B Powles,M S Van der Heijden,Y Loriot et al.
T B Powles et al.
Background: At the primary analysis of the EV-302 trial, enfortumab vedotin plus pembrolizumab (EV+P) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and o...
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study [0.03%]
恩Fortumab Vedotin加派姆单抗与化疗治疗局部晚期或转移性尿路上皮癌患者的患者报告结果：一项开放标签、随机对照的III期试验（EV-302）
Shilpa Gupta,Yohann Loriot,Michiel S Van der Heijden et al.
Shilpa Gupta et al.
Background: In the ongoing EV-302 trial, first-line enfortumab vedotin plus pembrolizumab improved progression-free survival and overall survival versus platinum-based chemotherapy in patients with locally advanced or met...
Clinical Trial
The Lancet. Oncology. 2025 Jun;26(6):795-805. DOI:10.1016/S1470-2045(25)00158-5 2025
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer [0.03%]
帕博利珠单抗治疗局部晚期或转移性尿路上皮癌二线或三线疗效分析
Tomohiro Matsuo,Yasuyoshi Miyata,Junki Harada et al.
Tomohiro Matsuo et al.
Background/aim: Pembrolizumab is widely used as second-line (2L) chemotherapy for unresectable advanced urothelial carcinoma (UC). While its anticancer effects are known, survival data, particularly on metastatic status, ...
Maximizing Outcomes with Chemoimmunotherapy in Lymph Node-only Metastatic Urothelial Cancer: Targeting a Favorable Subgroup [0.03%]
淋巴结转移性尿路上皮癌的化疗免疫治疗疗效最大化：针对有利亚组
Charles B Nguyen,Wesley Yip
Charles B Nguyen
耗时 0.21116 秒，为您在
48206918
条记录里面共找到 1024 篇文章 [XML]